Ditchcarbon
  • Contact
  1. Organizations
  2. Itamar Medical Ltd.
Public Profile
Medical Device Manufacturing
IL
updated 14 days ago

Itamar Medical Ltd. Sustainability Profile

Company website

Itamar Medical Ltd., a pioneering name in the medical technology sector, is headquartered in Israel (IL) and operates extensively across global markets. Founded in 1997, the company has established itself as a leader in the development of innovative solutions for sleep and cardiovascular disorders. Itamar Medical is renowned for its flagship product, WatchPAT, a unique home sleep apnea testing device that combines advanced technology with user-friendly design, setting it apart in the industry. The company’s commitment to enhancing patient care and improving diagnostic accuracy has earned it a prominent position in the healthcare landscape. With a focus on non-invasive monitoring solutions, Itamar Medical continues to achieve significant milestones, contributing to advancements in sleep medicine and cardiovascular health.

DitchCarbon Score

How does Itamar Medical Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

63

Industry Average

Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

27

Industry Benchmark

Itamar Medical Ltd.'s score of 63 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.

79%

Let us know if this data was useful to you

Itamar Medical Ltd.'s reported carbon emissions

Inherited from Asahi Kasei Corporation

Itamar Medical Ltd., headquartered in Israel (IL), currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Asahi Kasei Corporation, which may influence its climate commitments and reporting practices. Asahi Kasei Corporation, the parent company, has established various climate initiatives, but specific reduction targets or achievements for Itamar Medical Ltd. have not been disclosed. The absence of documented reduction targets or climate pledges indicates that Itamar Medical Ltd. may still be in the early stages of formalising its sustainability strategy. Given the lack of direct emissions data and specific commitments from Itamar Medical Ltd., it is essential to monitor future disclosures for any developments in their carbon emissions reporting and climate action initiatives.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201320142015201620172018201920202021202220232024
Scope 1
-
0,000,000,000
-
-
-
-
-
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
Scope 2
-
0,000,000,000
-
-
-
-
-
0,000,000,000
000,000,000
0,000,000,000
000,000,000
000,000,000
Scope 3
-
-
0,000,000,000
0,000,000,000
00,000,000,000
00,000,000,000
00,000,000,000
00,000,000,000
00,000,000,000
00,000,000,000
00,000,000,000
00,000,000,000

How Carbon Intensive is Itamar Medical Ltd.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Itamar Medical Ltd.'s primary industry is Medical, precision and optical instruments, watches and clocks (33), which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Itamar Medical Ltd.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Itamar Medical Ltd. is in IL, which has a low grid carbon intensity relative to other regions.

Itamar Medical Ltd.'s Scope 3 Categories Breakdown

Itamar Medical Ltd.'s Scope 3 emissions, which decreased by 0% last year and increased by approximately 113% since 2015, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 79% of total emissions under the GHG Protocol, with "End-of-Life Treatment of Sold Products" being the largest emissions source at 41% of Scope 3 emissions.

Top Scope 3 Categories

2024
End-of-Life Treatment of Sold Products
41%
Purchased Goods and Services
35%
Use of Sold Products
12%
Fuel and Energy Related Activities
6%
Capital Goods
4%
Upstream Transportation & Distribution
2%
Waste Generated in Operations
<1%
Employee Commuting
<1%
Business Travel
<1%

Itamar Medical Ltd.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Itamar Medical Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy